8-K: NeoGenomics Reports Strong Q4, Full Year 2025 Growth

NeoGenomics, Inc. announced double-digit revenue growth for Q4 and full year 2025, alongside the imminent clinical launch of its RaDaR ST MRD assay and positive 2026 financial guidance.

Summary

• Consolidated revenue for the fourth quarter of 2025 increased 11% to $190 million, and full year consolidated revenue increased 10% to $727 million.
• Fourth quarter net loss decreased 36% to $10 million, while full year net loss increased 37% to $108 million.
• Fourth quarter adjusted EBITDA increased 13% to $13 million, and full year adjusted EBITDA increased 9% to $43 million.
• Clinical revenue grew 15% for the full year, or 13% excluding the Pathline acquisition.
• Next-Generation Sequencing (NGS) revenue grew 23% in Q4 and 22% for the full year, outpacing market growth.
• The company successfully resolved RaDaR ST patent litigation and plans an imminent clinical launch of its RaDaR ST MRD assay, targeting a $20+ billion market.
• Cash and cash equivalents totaled $160 million at quarter end, a decrease from $367 million at the end of 2024.
• Full-year 2026 guidance projects consolidated revenue between $793 million and $801 million (9%-10% YOY growth), net loss between $(63) million and $(50) million (42%-54% decrease in loss), and adjusted EBITDA between $55 million and $57 million (27%-31% YOY growth).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive due to strong revenue growth, strategic product advancements like the RaDaR ST launch, resolution of patent litigation, and robust 2026 financial guidance projecting improved profitability, despite an increase in full-year net loss for 2025.

Positives

• Consolidated revenue increased 11% to $190 million in Q4 2025 and 10% to $727 million for the full year 2025.
• Clinical revenue grew 15% for the full year, or 13% excluding the Pathline acquisition.
• Next-Generation Sequencing (NGS) revenue grew 23% in Q4 and 22% for the full year, exceeding market growth rates.
• Net loss for Q4 2025 decreased 36% to $10 million compared to $15 million in Q4 2024.
• Adjusted EBITDA increased 13% to $13 million in Q4 2025 and 9% to $43 million for the full year 2025.
• Successfully resolved RaDaR ST patent litigation, removing a potential legal overhang.
• Imminent clinical launch of the RaDaR ST MRD assay, targeting a substantial $20+ billion molecular residual disease monitoring market.
• Strong 2026 financial guidance projecting 9%-10% revenue growth, a significant 42%-54% reduction in net loss, and 27%-31% growth in adjusted EBITDA.

Negatives

• Full year net loss increased 37% to $108 million in 2025 from $79 million in 2024.
• Cash and cash equivalents significantly decreased to $160 million at December 31, 2025, from $367 million at December 31, 2024.
• Net cash provided by operating activities decreased to $5.23 million in 2025 from $7.02 million in 2024.
• Net cash used in investing activities shifted to $(12.34) million in 2025 from $12.86 million provided in 2024.
• Significant net cash used in financing activities of $(200.29) million in 2025, primarily due to convertible debt repayment.
• Lower non-clinical revenue due to macro trends in the pharmaceutical and biotech industries, and a less favorable test mix.

Risks

• Ability to identify and implement appropriate financial and operational initiatives to improve performance.
• Ability to identify and recruit executive candidates.
• Ability to continue gaining new customers.
• Ability to offer new types of tests.
• Ability to integrate acquisitions and otherwise implement its business plan.
• General risks and uncertainties identified in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other SEC filings.

Future Outlook

NeoGenomics anticipates continued strong performance in 2026, projecting consolidated revenue between $793 million and $801 million, representing 9%-10% year-over-year growth. The company expects a significant reduction in net loss, forecasting between $(63) million and $(50) million, and adjusted EBITDA to grow to $55 million to $57 million. The clinical launch of the RaDaR ST MRD assay is expected to contribute modestly to revenue in 2026, with substantial longer-term opportunities projected for 2027 and beyond, driving future revenue growth alongside the PanTracer family of therapy selection solutions.

Management Comments

• "We ended 2025 on a strong note, delivering double-digit revenue growth in the fourth quarter on the strength of our clinical volumes and ongoing mix shift toward higher value tests."
• "Notably, NGS grew 23% in Q4 and 22% for the full year, both well ahead of the market growth rate, reflecting our ability to successfully pull innovation through the community channel, where we enjoy a leadership position and where approximately 80% of all cancer care is delivered today."
• "Looking ahead, the imminent clinical launch of our RaDaR ST MRD assay further enhances our menu of advanced tests and allows us to address the $20+ billion molecular residual disease monitoring market."
• "And while we anticipate modest revenue contribution from MRD in 2026, we believe the longer-term opportunity, in 2027 and beyond, is substantial."
• "We believe RaDaR ST, together with our PanTracer family of therapy selection solutions, will be a key driver of our revenue growth over the long term."
• "We envision a world where every cancer treatment decision is as personal as the patient, and this drives what we do every day. I am pleased with our progress in 2025 and excited about our current momentum."

Industry Context

StockSavvy.ai notes that NeoGenomics' strong growth in NGS and the strategic launch of its RaDaR ST MRD assay align with the broader industry trend towards precision medicine and personalized cancer diagnostics. The molecular residual disease (MRD) monitoring market is a rapidly expanding segment within oncology, offering significant growth potential for companies with advanced diagnostic solutions. NeoGenomics' focus on the community channel, where most cancer care is delivered, positions it well to capitalize on these trends.

Legal Proceedings

• Successfully resolved RaDaR ST patent litigation.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, strategic product launches, and positive 2026 guidance, but tempered by increased full-year net loss and significant cash outflow from debt repayment.
• Customers (oncologists, pathologists, hospital systems, academic centers, pharmaceutical firms): Benefit from an enhanced menu of advanced diagnostic tests, including the upcoming RaDaR ST MRD assay, enabling precision medicine.
• Employees: Higher compensation and benefit costs were noted, indicating potential positive impact on employee remuneration.
• Pharmaceutical and biotech industries: Experienced lower non-clinical revenue due to macro trends, indicating a potential negative impact on this segment of the business.

Next Steps

• Clinical launch of the RaDaR ST MRD assay.
• Conference call to discuss fourth quarter and full year 2025 results on February 17, 2026, at 8:30 a.m. Eastern Time.

Key Dates

Recommendation

NeoGenomics demonstrates strong underlying business momentum with double-digit revenue growth, particularly in high-value NGS tests, and a clear strategic path with the imminent launch of the RaDaR ST MRD assay into a multi-billion dollar market. While the full-year 2025 net loss increased, the significant improvement in Q4 net loss and the robust 2026 guidance projecting substantial reductions in net loss and strong Adjusted EBITDA growth indicate a positive inflection point for profitability. The successful resolution of patent litigation also removes a key uncertainty. These factors, combined with the company's leadership in the community cancer care channel, suggest strong future potential that may not be fully reflected in the current valuation, making it an attractive 'buy' for long-term investors.

Keywords

Oncology diagnostics, Cancer genetics testing, Precision medicine, Next-Generation Sequencing, NGS, Molecular Residual Disease, MRD, RaDaR ST, Financial results, Revenue growth, Adjusted EBITDA, Pathline acquisition, Biotech industry, Pharmaceutical industry